ANI Pharmaceuticals (NASDAQ:ANIP) Posts Quarterly Earnings Results

ANI Pharmaceuticals (NASDAQ:ANIP) announced its quarterly earnings data on Thursday. The specialty pharmaceutical company reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.18 by $0.52, FiscalAI reports. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm had revenue of $290.78 million during the quarter, compared to analyst estimates of $280.26 million. During the same period in the previous year, the business posted $2.04 EPS. The business’s quarterly revenue was up 27.6% on a year-over-year basis.

Here are the key takeaways from ANI Pharmaceuticals’ conference call:

• ANI reported third-quarter revenue of $290.8 million, up 28% year over year, and adjusted EBITDA of $83.3 million, up 40%; adjusted diluted EPS rose to $2.70. Generics revenue increased 11% to $104.5 million, while ILUVIEN revenue grew 34% to $22.3 million.
• Cortrophin Gel revenue was $138.7 million, below expectations, as specialty-pharmacy capacity constraints and slower onboarding at new gout prescribers delayed conversion of cases to patients on therapy. ANI cut 2026 Cortrophin guidance to $480 million–$500 million from $520 million–$540 million, while citing strong demand and steps to improve fulfillment.
• ANI updated 2026 total revenue guidance to $1.085 billion–$1.125 billion and raised adjusted EBITDA guidance to $290 million–$300 million and adjusted EPS guidance to $9.37–$9.71; ILUVIEN guidance also increased to $80 million–$85 million. The company said strong profitability and favorable product mix support the higher earnings outlook.
• ANI announced an all-cash offer for Egetis Therapeutics valuing its equity at $560 million, adding EMCITATE, the first approved treatment for MCT8 deficiency, to its rare-disease portfolio. ANI sees peak annual sales potential above $300 million and expects to leverage its commercial infrastructure, though the deal is expected to dilute adjusted EPS in year one and raise pro forma net leverage to about 2.7x.

ANI Pharmaceuticals Trading Down 2.8%

ANIP traded down $2.03 during trading on Thursday, hitting $69.62. 1,295,657 shares of the stock traded hands, compared to its average volume of 334,087. The firm has a market capitalization of $1.60 billion, a P/E ratio of 15.00, a price-to-earnings-growth ratio of 2.31 and a beta of 0.45. ANI Pharmaceuticals has a 12-month low of $68.79 and a 12-month high of $95.45. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The firm has a 50-day moving average of $72.65 and a 200 day moving average of $77.41.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ANIP shares. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 target price on the stock. Canaccord Genuity Group dropped their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Guggenheim dropped their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Finally, Oppenheimer assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $99.60.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Q3 adjusted earnings were $2.70 per share, above the roughly $2.18 analyst consensus and up from $2.04 a year earlier. Revenue of $290.78 million also topped estimates of about $280 million and increased 27.6% year over year. ANI Pharmaceuticals Q3 results
• Neutral Sentiment: ANI proposed a recommended public offer for Swedish biotech Egetis Therapeutics valued at SEK 5.6 billion (about $560 million). ANI says the acquisition would expand the scale and scope of its rare-disease business; its ultimate impact will depend on completion and the value generated. ANI offer for Egetis Therapeutics
• Negative Sentiment: The acquisition’s substantial price may raise concerns about funding, integration and execution, potentially weighing on shares even as quarterly results beat expectations. ANI offers $560 million for Egetis

Insider Transactions at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction dated Tuesday, October 13th. The stock was sold at an average price of $73.59, for a total value of $36,795.00. Following the sale, the vice president directly owned 73,424 shares of the company’s stock, valued at $5,403,272.16. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 2,850 shares of the firm’s stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $72.87, for a total value of $207,679.50. Following the completion of the sale, the chief financial officer directly owned 166,143 shares in the company, valued at $12,106,840.41. The trade was a 1.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 30,412 shares of company stock valued at $2,220,970. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.